Synthetic Cyclic C5-Curcuminoids Mitigate Oxidative, Apoptotic and Inflammatory Damage in a 6-OHDA-Induced Neuron–Microglia Co-Culture Model of Neuronal Damage Authors: Edina Pandur, Zsombor Bence Tóth, Levente Tyukodi, Ilona Gróf, Szilvia Veszelka, Mária A. Deli, Zsuzsanna Rozmer, Imre Huber Published: 2026 ABSTRACT Curcumin and natural curcuminoids possess numerous beneficial properties, including antioxidant, antitumor, and anti-inflammatory effects. However, their application is challenging because of instability and rapid metabolism. Cyclic C5-curcuminoids, a subgroup of curcuminoids, are chemically more stable and less susceptible to hydrolysis or metabolism. In our study, seven synthetic compounds—five cyclic C5-curcuminoids (compounds 8, 9, 11, 12, and 13) and two cyclic chalcones (compounds 4 and 5)—were examined using an in vitro 6-hydroxydopamine-induced neuronal damage model established with all-trans retinoic acid-differentiated SH-SY5Y and BV-2 microglial cells. The antioxidant, anti-apoptotic (including ferroptosis markers (iron, GSH/GSSG, and malondialdehyde)), apoptotic (PARP, cytochrome c, caspase 9, active caspase-3, and oligonucleosome release), and anti-inflammatory effects of these compounds were also investigated. Compounds 5, 9, 12, and 13 significantly decreased reactive oxygen species production (percentage changes: 5: 28.9%; 9: 32%; 12: 29.8%; 13: 49.2%) and increased antioxidant capacity (percentage changes: 5: 63.4%; 9: 85.8%; 12: 31.2%; 13: 85.9%) and antioxidant enzyme activity (catalase, superoxide dismutase, and glutathione peroxidase) in SH-SY5Y cells. Compounds 5, 9, and 12 decreased microglial activation by downregulating Iba1 expression (fold changes: 5: 0.73; 9: 0.39; 12: 0.33) and decreasing glutamate concentration (percentage changes: 5: 26.5%; 9: 41.2%; 12: 27.3%). Together with compound 13, they reduced pro-inflammatory cytokine (IL-6, TNFα) secretion and induced anti-inflammatory cytokine (IL-10) release in SH-SY5Y and BV-2 cells. Based on these results, the blood–brain barrier penetrations of compounds 5, 9, 12, and 13 were also investigated. The highest blood–brain barrier penetration was observed for compound 12 (Papp value 13.6 × 10−6 cm/s). Synthetic cyclic C5-curcuminoids derived from curcumin overcome the limitations of stability and bioavailability and exhibit strong antioxidant, anti-inflammatory, and anti-apoptotic effects, making them promising candidates for treating neurodegenerative diseases. 1. Introduction Plants with a long history in traditional medicine are an unbeatable source of lead molecules, offering valuable insights into synthetic strategies in pharmaceutical research and development [1,2]. Curcumin, the main component of turmeric (Curcuma longa L. and Curcuma domestica L., Zingiberaceae), is an excellent example of a compound with diverse pharmacological properties. The isolation of another natural product, C5-curcumin, from the same plant was reported in 1993 (Figure 1) [3]. While it remains unclear if C5-curcumin is a metabolite of curcumin, the truncated molecule, C5-curcumin, can be produced from curcumin through the process of pyrolysis [4]. According to recent review articles, curcumin, as a polyphenol, has shown anti-inflammatory, antiradical, antioxidant, anti-cancer, and multi-drug-resistance-reverting (MDR) activities [5,6,7]. A special scientific focus has been placed on the neuroprotective ability of curcumin [8,9] and in terms of Parkinson’s disease [10]. Studies have also been conducted to demonstrate the neuroprotective efficacy of natural curcuminoids (Figure 1) [11,12]. In addition, curcumin has protective effects on the blood–brain barrier (BBB) in animal and culture models of diseases [13]. However, their medical use is limited by the shortcomings of curcumin and other natural curcuminoids. The most important difficulties with their use are the chemical “(in)stability” (quick metabolism) and poor bioavailability of the structure [13,14]. Another direction in the medicinal chemistry of curcumin is to overcome these limitations by designing and developing more stable analogs of synthetic curcuminoids. An example of this is the neuroprotective synthetic C5-curcuminoids. Two of the tested synthetic C5-curcuminoids (R = OCH3 and R = Cl; Figure 1) improved cognition and reduced the progression of dementia in mice, including in vitro, in vivo tests, and molecular docking validation [15]. A further synthetic possibility is the preparation of an even more stable subgroup of curcuminoids, the so-called cyclic C5-curcuminoids (Figure 2) [16]. Structure–activity studies (SAR) were performed, for example, in order to find an optimal 3D molecular shape for optimal cytotoxic effect through necessary structural modifications [17,18,19]. The central ring of the synthetic cyclic C5-curcuminoids reduces the conformational flexibility to a minimum and constrains the molecules into a “near-to-planar” shape compared to curcumin or C5-curcumin. In addition to superior efficacy, synthetic cyclic derivatives have been proven to be chemically more stable and less susceptible to hydrolysis or metabolism [20]. No publications have been identified that discuss synthetic cyclic C5-curcuminoids in relation to neurodegenerative diseases, such as Alzheimer’s or Parkinson’s disease, particularly in a neuroprotective context. Therefore, we selected examples from various pharmacological fields to illustrate the chemical stability of these synthetic curcumin analogs. Compounds A, B, and C (Figure 2) performed well in the different cytotoxicity tests. In addition to its effects on ovarian cancer cells, derivative A is a concomitant antioxidant [21]. Compound B exhibited high toxicity against neuroblastoma (IC50 = 0.14 nM) and astrocytoma cells (IC50 = 0.39 nM) in parallel and could penetrate the blood–brain barrier [22]. Compounds C, the newest subgroup of cyclic C5-curcuminoids, hold a unique central ring based on 4-hydroxycyclohexanone and are active antiproliferatives that do not interact with DNA [23]. Synthetic cyclic chalcones (D, Figure 2) are a subgroup of the chalcone family and are strongly related to cyclic C5-curcuminoids due to their aromatic enone moiety [24]. Moreover, it has also been demonstrated that synthetic C5-curcuminoids possess anti-cancer activity in carcinoma cell lines by enhancing oxidative stress, ferroptosis, and apoptosis [25]. As synthetic cyclic C5-curcuminoids have not yet been studied in neurodegenerative models, we established a 6-OHDA-induced neuronal damage model using differentiated SH-SY5Y cells. In our previous study, we described the antioxidant effects of novel synthetic cyclic C5-curcuminoids. However, their anti-apoptotic and anti-inflammatory effects remained uncharacterized [26]. In the continuation of the study, microglia, the brain’s immune cells, were involved, as these cells play a key role in the process of neurodegeneration by regulating inflammation [27,28,29]. Oxidative stress in the brain affects microglia activation and enhances the release of pro-inflammatory cytokines as well as glutamate from immune cells, leading to neurotoxicity [30,31]. Moreover, activated microglia further increase oxidative stress, leading to severe neuronal damage by increasing the rate of programmed cell death [32,33]. In the present study, we established a co-culture system using all-trans-retinoic acid-differentiated SH-SY5Y cells and BV-2 microglia. The presence of microglia mimics the brain’s immune system, and their effects on neurons can be monitored. Therefore, we demonstrated the beneficial effects of synthetic cyclic C5-curcuminoids and chalcones, even in the presence of microglia, which can contribute to neuronal loss. Differentiated SH-SY5Y cells were treated with 6-OHDA to induce an oxidative stress environment, and BV-2 microglia were added to the cultures on sterile coverslips. This model, called bilaminar co-culture, ensures physical interactions between cells and the free diffusion of chemicals. This study aimed to examine the antioxidant effects of seven synthetic cyclic compounds, cyclic C5-curcuminoids (compounds 8, 9, 11, 12, and 13) and chalcones (compounds 4 and 5), in the presence of microglia, considering their modulatory properties. Additionally, we investigated whether these compounds inhibit neuronal death and decrease the production of inflammatory cytokines in both neurons and microglia. Furthermore, the study assessed the ability of synthetic cyclic C5-curcuminoids to attenuate the pro-inflammatory effects of microglia and mitigate neuronal damage. When selecting the compounds, the couples (4 and 5, 8 and 9, or 11 and 12) formed two chemical groups. One is the phenolic group (5, 9, 12, and 13); the other one is the non-phenolic group (4, 8, and 11). The two groups were also separated pharmacologically in the SAR analysis. In addition, the BBB penetration of compounds 5, 9, 12, and 13 was also determined using a well-established and characterized human blood–brain barrier (BBB) co-culture model [34]. Our objective was to identify a drug candidate with the potential to develop therapy for neurodegenerative disorders. 2. Materials and Methods 2.1. Chemical Experimental Protocol A Barnstead-Electrothermal 9100 apparatus (Thermo Fisher Scientific Inc., Waltham, MA, USA) was used to ascertain the uncorrected melting points. Silica gel 60 (0.2–0.5 mm, Merck Life Sciences Kft., Budapest, Hungary) was used for column chromatography, and pre-coated silica gel 60 (F-254, Merck Life Sciences Kft., Budapest, Hungary) plates were used for TLC. The nuclear magnetic resonance (NMR) 1H- and 13C-spectra were recorded using a Bruker Avance III 500 (500.15/125.77 MHz for 1H/13C) spectrometer (Bruker Corp., Ettlingen, Germany) according to our previous publication [22]. The chemical shifts were calibrated against the residual solvent signals. The measurements were conducted at a probe temperature of 298 K using dimethyl sulfoxide (DMSO)-d6 solution. All 1H and 13C NMR spectra were consistent with the expected structures. Analyses were performed using a Thermo Dionex UltiMate 3000 HPLC (Dionex, Sunnyvale, CA, USA) system coupled to a Thermo Q Exactive Focus quadrupole-Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Chromatographic separation was carried out on a Thermo Accucore RP-MS analytical column (150 × 2.1 mm, 2.6 µm; Thermo Scientific). Eluent A was 0.1% formic acid in water, and eluent B was 0.1% formic acid in methanol. The gradient was 0.0 min, 20% B; 5.0 min, 90% B; 8.5 min, 90% B; and 9.0 min, 20% B, followed by 1.0 min re-equilibration in initial conditions (total run time: 10.0 min). The column was maintained at 40 °C, the flow rate was 0.3 mL/min, and the injection volume was 2 µL. Under these conditions, the analytes were eluted at approximately 4.0 min (12), 5.2 min (13), 5.3 min (9), and 6.0 min (5). The mass spectrometer was equipped with a heated electrospray ionization (HESI) source operating in positive ion mode. The spray voltage was 4.4 kV, capillary (ion transfer tube) temperature was 260 °C, sheath gas flow rate was 30 (arbitrary units), auxiliary gas flow rate was 10 (arbitrary units), and auxiliary gas heater temperature was 300 °C. Full-scan spectra were acquired over m/z 110–1100 at a resolving power of 35,000 (FWHM at m/z 200), with an automatic gain control (AGC) target of 3 × 106 and the maximum injection time set to auto. Each analyte was quantified from the extracted ion chromatogram (EIC) of its protonated molecule [M+H]+ using a ±5 ppm mass tolerance: 9, m/z 383.1489 (C22H22O6); 5, m/z 267.1016 (C17H14O3); 12, m/z 368.1493 (C21H21NO5); and 13, m/z 468.1653 (C25H25NO8). EICs were extracted using 7-point Gaussian smoothing and integrated using the Genesis algorithm with the default software parameters. Data were acquired and processed with Q Exactive Focus 2.11 and Xcalibur 4.2 software (Thermo Fisher Scientific Inc., Waltham, MA, USA) [26]. The compounds used in this study were resynthesized. Their physical and analytical parameters were identical to those of the previously prepared ones. 2.2. Cell Culture Conditions for the BBB Model Blood was collected from the umbilical cord at Béthune Maternity Hospital (Béthune, France), and CD34+ cells were isolated at the Laboratory of Barrière Hémato-Encéphalique (LBHE), managed by Pr. Maxime Culot. LBHE is the supervisory authority of the Université d’Artois (Arras, France), which is the co-owner of a patent for a human in vitro BBB model based on the use of human CD34+ cells from cord blood co-cultivated with brain pericytes (patent number: WO2014/203087). According to French legislation, all research protocols regarding the collection of umbilical cord blood, isolation of cells, and use of cells derived from human cord blood were approved by the French Ministry of Higher Education and Research (ethical approval number: CODECOH 2011-1321). Written informed consent was obtained from the families before entering the study, stating that umbilical cord blood was collected by Béthune Maternity Hospital and CD34+ cells were isolated by Université d’Artois. CD34+ hematopoietic stem cells were differentiated into endothelial cells (hEC). The Université d’Artois is allowed to negotiate and sign contracts/collaborations with other partners necessary for the exploitation of hEC cells. hEC stocks were purchased from Université d’Artois in the framework of a Material Transfer Agreement between Université d’Artois (Prof. Maxime Culot, Arras, France) and HUN-REN Biological Research Centre (Szeged, Hungary). hEC cells were placed in sterile vials after cryopreservation (approx. 106 CD34+-derived endothelial cells/vial) and transported in a dry ice package from Université d’Artois directly to the recipient laboratory, Prof. Mária A. Deli, HUN-REN Biological Research Centre, and her research group, for the establishment and examination of a BBB co-culture model based on cord blood-derived human endothelial cells in co-culture with brain pericytes in this publication. Throughout the transport, the carrier complied with the regulations governing the transport of biological materials in the EU. Hematopoietic stem cell-derived human endothelial cells (hEC) [35] were cultured in endothelial cell culture medium (ECM; ScienCell Research Laboratories, Carlsbad, CA, USA) supplemented with 5% FBS (ScienCell Research Laboratories, Carlsbad, CA, USA), 1% endothelial cell growth supplement (ECGS; ScienCell Research Laboratories, Carlsbad, CA, USA), and 50 μg/mL gentamicin (Merck Life Sciences Kft., Budapest, Hungary). For the experiments, hEC (passage number 7) were either grown in co-culture or received conditioned medium from bovine brain pericytes (bPCs) to acquire brain-like properties [35]. Brain pericytes were isolated and maintained as described previously [35] and cultured in 0.2% gelatin-coated 100 mm Costar Petri dishes (Corning Inc., New York, NY, USA) in DMEM (Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 20% FBS, 1% GlutaMAX (Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA), and 50 μg/mL gentamicin. Before the experiments, hEC or the BBB co-culture model was treated with a cARLA cocktail for 2 days [35]. All cultures were maintained in a humidified incubator at 37 °C with 5% CO2. 2.3. Working Solutions Stock solutions of 10 mM compounds 5, 9, 12, and 13 were prepared in DMSO (Merck Life Sciences Kft., Budapest, Hungary). Working solutions were diluted in the culture medium to 0.1, 1, and 10 µM concentrations for cell viability experiments. For the permeability experiment, working solutions were diluted in Ringer-Hepes (150 mM NaCl, 5.2 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 0.2 mM MgCl2, 5 mM D-glucose, 6 mM NaHCO3, 10 mM HEPES, pH 7.4) containing 1% bovine serum albumin (BSA) (Merck Life Sciences Kft., Budapest, Hungary) at a concentration of 1 µM, based on cell viability data. 2.4. Impedance Measurements by Real-Time Cell Microelectronic Sensing To measure the cellular response to the compounds, we used an RTCA-SP instrument (Agilent Technologies, Santa Clara, CA, USA). This impedance-based label-free technique has been used by our team for the dynamic monitoring of living cells in real-time and non-invasive quantification of adherent cell proliferation and viability [36]. The RTCA-SP system utilizes 96-well plates containing gold microelectronic sensor arrays (E-plate; Agilent Technologies, Santa Clara, CA, USA). The interaction between cells and electrodes generates an impedance response that correlates linearly with cell number, adherence, and cell growth. This method is more sensitive and informative than colorimetric end-point assays for testing damage or functional changes in brain endothelial cells [37]. The E-plates were coated with collagen IV (100 μg/mL) and fibronectin (25 μg/mL) solution. Culture medium (50 μL) was added to each well for background readings, and 50 µL of human brain endothelial cell suspension was dispensed at a density of 4 × 103 cells/well. The cell index at each time point was defined as (Rn–Rb)/15, where Rn is the cell–electrode impedance of the well containing the cells, and Rb is the background impedance of the well containing the medium alone. The cells were grown for 3–5 days until reaching confluency, which was registered as a plateau phase of the cell index, and then treated with the compounds for 24 h. The results are expressed as normalized cell indices. As a reference compound to induce cell death, TX-100 detergent was used at 1% concentration. 2.5. Human Co-Culture Model of the BBB for Permeability Studies Permeability measurements were performed using a human cell-based BBB co-culture model in which hECs and bPCs were used [35]. To assemble the BBB model, bPCs (passage number < 15) were trypsinized and seeded at the bottom of collagen IV-coated (100 μg/mL) cell culture inserts (polycarbonate membrane, 0.4 μm pore size, 1.12 cm2, Corning Inc., New York, NY, USA) at a density of 2 × 104 cells/cm2. After seeding, bPCs were allowed to attach to the bottom of the insert for 1 h at 37 °C, and then the insert was turned and placed in a 12-well plate containing endothelial culture medium. hECs were then seeded at a density of 6 × 104 cells/cm2 to the other, upper side of the insert coated with collagen IV (100 μg/mL; Merck Life Sciences Kft., Budapest, Hungary) and fibronectin (25 μg/mL; Merck Life Sciences Kft., Budapest, Hungary) in hEC medium. On the fourth day of culture, the luminal compartment of the BBB model was treated with cARLA for 48 h, and experiments were performed on the sixth culture day. 2.6. Permeability Experiment To measure the BBB permeability of compounds 5, 9, 12, and 13 in the luminal-to-abluminal direction mimicking blood-to-brain transfer, the culture inserts were transferred to 12-well plates containing 1500 μL of 0.1% BSA and 0.1% DMSO-Ringer-Hepes buffer in the bottom/acceptor compartments. In the upper/donor compartments, the culture medium was replaced with 500 μL of buffer containing different curcuminoid derivatives at a concentration of 1 µM. To test the function of the BBB model, the flux of permeability marker molecules sodium fluorescein (SF, 10 μg/mL, 376 Da) and Evans blue-labeled albumin (EBA, 10 mg/mL BSA +167.5 μg/mL Evans blue dye, 67 kDa) was also determined. The plates were incubated at 37 °C in 5% CO2 for 1 h on a horizontal shaker (~120 rpm). The concentrations of the marker molecules were measured using a Fluorolog-3 fluorescence spectrofluorometer (Horiba Jobin Yvon Inc., Edison, NJ, USA) at 584 nm excitation and 680 nm emission wavelengths for EBA and 485 nm excitation and 520 nm emission wavelengths for SF. After incubation, samples from both compartments were collected in low-retention tubes and analyzed. After the permeability assay, the insert membranes were cut out, and the cells were dissolved in 1 mL of 75% ethanol. Compound concentrations were measured using LC-MS analysis. The quantification of curcuminoid derivatives (LOD and LOQ determinations) is provided in the Supplementary Materials [38]. 2.7. Calculation of Apparent Permeability Coefficients The apparent permeability coefficients (Papp) were calculated as described in our previous study [34]. The cleared volume was calculated from the concentration difference of the derivatives in the bottom/acceptor compartment ([C]B) after 1 h and top/donor compartments at 0 h ([C]A), the volume of the bottom/acceptor compartment (VB; 1.5 mL), and the surface area available for permeability (A; 1.12 cm2) using the following equation [34]:Papp=[C]B×VBA×[C]A × t 2.8. Calculation of Mass Balance The mass balance/recovery was calculated from the concentrations of compounds 5, 9, 12, and 13 in the top/donor compartment (CfA), the bottom/acceptor compartment (CfB), the initial concentration of the treatment solutions in the top/donor compartment (C0A), and the volumes of the top/donor (VA; 0.5 mL) and bottom/acceptor compartments (VB; 1.5 mL) using the following equation [22]:%Mass balance=CfAVA+CfBVBC0AVA×100% The mass balance was corrected using the concentrations of compounds 5, 9, 12, and 13 in the cells (in 1 mL of 75% ethanol) or remaining absorbed to the cell-free, empty membranes. 2.9. Neuron–Microglia Co-Cultures and Treatments SH-SY5Y human neuroblastoma cells (ATCC-CRL-2266) were maintained in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 medium (DMEM/F12; Capricorn Scientific GmbH, Ebsdorfergrund, Germany). BV-2 murine microglial cells (a gift from Prof. Dr. László Tretter, Semmelweis University, Budapest, Hungary) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; VWR International Kft., Debrecen, Hungary). Both cell culture media were supplemented with 10% fetal bovine serum (FBS; Capricorn Scientific GmbH, Ebsdorfergrund, Germany) and 1% penicillin/streptomycin (P/S; Capricorn Scientific GmbH, Ebsdorfergrund, Germany). DMEM/F12 medium also contained 1% non-essential amino acid solution (NEAA, Capricorn Scientific GmbH, Ebsdorfergrund, Germany). The SH-SY5Y cells were differentiated using 1 μM all-trans retinoic acid (Merck Life Sciences Kft., Budapest, Hungary) for 5 days in serum-depleted (1% FBS) culture medium. 6-OHDA hydrobromide (Merck Life Sciences Kft., Budapest, Hungary) was dissolved in sterile distilled water to prepare a stock solution (50 mM). Differentiated cells were treated with freshly diluted 150 µM 6-OHDA [26] (Merck Life Sciences Kft., Budapest, Hungary) for 24 h before establishing co-culture systems. BV-2 cells were cultured in poly-L-ornithine (Merck Life Sciences Kft., Budapest, Hungary)-coated culture dishes (Sarstedt AG & Co. KG, Nümbrecht, Germany). During the 24 h pre-treatment of SH-SY5Y cells, BV-2 cells were seeded onto 22 mm sterile coverslips coated with poly-L-ornithine. After an overnight resting period, bilaminar co-cultures were established the following day by turning the BV-2 cells containing coverslips upside down, facing the differentiated and 6-OHDA pre-treated SH-SY5Y cells in fresh 1% serum-depleted DMEM/F12 culture medium (Figure 3). In the bilaminar culture, the cells were separated by a thin layer of culture medium. Therefore, physical and chemical contacts between cells are also possible. The cell cultures were prepared as described in our previous publications [39,40]. The co-cultured cells were treated with seven synthetic cyclic compounds (4, 5, 8, 9, 11, 12, and 13) for 24 h. Rasagiline (Merck Life Sciences Kft., Budapest, Hungary), a monoamine oxidase B inhibitor used to treat Parkinson’s disease, was used as the positive control in the experiments at a concentration of 1 µM for 24 h. The optimal treatment concentrations were determined according to the IC50 values (compound 4: 9.14 ± 1.13 µM; compound 5: 18.11 ± 2.11 µM; compound 8: 6.23 ± 1.09 µM; compound 9: 15.11 ± 1.03 µM; compound 11: 7.46 ± 1.14 µM; compound 12: 8.94 ± 1.23 µM; compound 13: 13.68 ± 1.22 µM) and our previous experiments on differentiated SH-SY5Y cells [26]. The treatment concentrations were selected based on preliminary ROS and TAC studies conducted in our previous publication [26]. The treatment concentrations were as follows: compound 4, 5 µM; compound 5, 10 µM; compound 8, 5 µM; compound 9, 10 µM; compound 11, 5 µM; compound 12, 5 µM; and compound 13, 10 µM [26]. The control cells were treated with DMSO (Merck Life Sciences Kft., Budapest, Hungary). These concentrations corresponded to approximately 55–80% of the IC50 value for each compound (ranging from 54.7% for compound 4 to 80.3% for compound 8). They were selected to remain within a pharmacologically active, sub-cytotoxic range for each compound individually, while maintaining consistency with the concentrations used in our previous SH-SY5Y monoculture study. Since the concentrations were neither equimolar across compounds nor matched to an identical IC50 fraction, this design did not support the direct comparison of compound potency. After the incubation period, the coverslips with BV-2 cells were separated from the surface of the differentiated SH-SY5Y cells, and the two cell types were investigated separately. 2.10. Reactive Oxygen Species Measurement SH-SY5Y cells were cultured in 24-well plates (Biologix Europe, Hallbergmoos, Germany) at a density of 5 × 104 cells/well. BV-2 cells were cultured on 13 mm poly-L-ornithine-coated coverslips (Thermo Fisher Scientific Inc., Waltham, MA, USA) for 24 h, and one coverslip was added to each well containing the differentiated SH-SY5Y cells as described in Section 2.9. After treatment and cell separation, ROS levels were measured in SH-SY5Y cells using a Fluorometric Intracellular ROS Kit (Cat. no.: MAK142; Merck Life Technologies Kft, Budapest, Hungary) according to the manufacturer’s instructions. The cells were incubated with 100 µL of ROS reagent for 30 min in a humidified atmosphere at 37 °C. Fluorescence intensity was measured at λex 640 nm/λem 675 nm using an EnSight Multimode microplate reader (PerkinElmer, Rodgau, Germany). ROS levels were compared to those in cells treated with DMSO as a control and expressed as a percentage relative to the control (100%) [25]. 2.11. Total Antioxidant Capacity Determination The total antioxidant capacity was measured using the Antioxidant Assay Kit (Cat. no.: MAK334; Merck Life Science Kft, Budapest, Hungary). SH-SY5Y cells were cultured in 6-well plates (Biologix Europe, Hallbergmoos, Germany) at a density of 5 × 105 cells/well. BV-2 cells were cultured on 22 mm poly-L-ornithine-coated coverslips (Sarstedt AG & Co. KG, Nümbrecht, Germany) for 24 h, and one coverslip was added to each well containing differentiated SH-SY5Y cells. After cell separation, SH-SY5Y cells were collected by centrifugation; then, the pellets were lysed in cold PBS, and 100 µL of each sample was used for measurements. Optical density was measured at 570 nm using a MultiSkan GO spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). Antioxidant capacity was expressed as Trolox equivalent in µM [25]. 2.12. Catalase Assay Intracellular catalase activity was determined using the Catalase Assay Kit (Cat. no.: MAK531; Merck Life Science Kft., Budapest, Hungary). Differentiated SH-SY5Y cells were cultured in 6 cm dishes (Biologix Europe, Hallbergmoos, Germany) at a density of 106 cells/dish. The co-cultures were established and treated as described above, except that three BV-2 cells containing coverslips were added to one culture dish. After cell separation, SH-SY5Y cells were collected by centrifugation, and the pellets were homogenized on ice in 50 mM potassium phosphate buffer containing 1 mM EDTA. The lysate was centrifuged at 10,000× g for 15 min at 4 °C, and the supernatant was used for measurements. After the assay was performed, the optical density was measured at 540 nm using a Multiskan GO spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Enzyme activity was calculated using the catalase activity equation and expressed in U/L. 2.13. Superoxide Dismutase (SOD) Activity Measurement Differentiated SH-SY5Y cells were cultured in 6 cm dishes (Biologix Europe, Hallbergmoos, Germany) at a density of 106 cells/dish. The co-cultures were established and treated as described above. After cell separation, the SH-SY5Y cells were collected by centrifugation. The Superoxide Dismutase Activity Assay Kit (Cat. no.: MAK528; Merck Life Science Kft., Budapest, Hungary) was used to determine SOD activity according to the manufacturer’s protocol. Briefly, the pellets were homogenized immediately after collection in a cold lysis buffer containing 0.1 M Tris-HCl, 0.5% Triton X-100, 5 mM mercaptoethanol, and protease inhibitors. The supernatants were then used for subsequent reactions. Optical density was measured at 440 nm using a Multiskan GO spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). SOD activity was expressed in U/mL [26]. 2.14. Glutathione Peroxidase (GPx) Assay Differentiated SH-SY5Y cells were cultured in 6 cm dishes (Biologix Europe, Hallbergmoos, Germany) at a density of 106 cells/dish. The co-cultures were established and treated as described above. Glutathione peroxidase activity was determined using a Glutathione Peroxidase Assay Kit (Cat. no.: MAK437; Merck Life Science Kft, Budapest, Hungary) according to the manufacturer’s protocol. Briefly, SH-SY5Y cells were homogenized in 200 µL of ice-cold 1× PBS by sonication. The supernatants were then used for subsequent reactions. OD was measured at 340 nm using a Multiskan GO spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). GPx activity was expressed in U/L [25]. 2.15. Intracellular Iron Content Determination Differentiated SH-SY5Y cells were cultured in 6-well plates (Biologix Europe, Hallbergmoos, Germany) at a density of 5 × 105 cells/well. Co-cultures were established and treated as previously described [41]. After separation, the SH-SY5Y and BV-2 cell pellets were homogenized in 50 mM NaOH at room temperature for 2 h, with gentle shaking. After incubation, the samples were mixed with an equal volume of 10 mM HCl. The samples were then mixed with an iron-releasing reagent (1.4 M HCl, 4.5% w/v) and incubated for 2 h at 60 °C. For iron detection, an iron detection reagent (6.5 mM ferrozine, 6.5 mM neocuproine, 2.5 M ammonium acetate, and 1 M ascorbic acid) was added to the mixtures and incubated at RT for 30 min. Optical density was measured at 550 nm using a Multiskan GO spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). A standard curve of FeCl3 was used to determine the iron concentration. The protein concentration was determined for each sample using a DC Protein Assay Kit (Cat. no.: 5000112; Bio-Rad Inc., Hercules, CA, USA) to normalize the iron levels, and the intracellular iron content was expressed as µM iron/mg protein [25]. 2.16. Glutathione (GSH/GSSG) Measurement Differentiated SH-SY5Y cells were cultured in 6 cm dishes (Biologix Europe, Hallbergmoos, Germany) at a density of 106 cells/dish. The co-cultures were established and treated as described above. The oxidized glutathione (GSSG) and total glutathione concentrations were measured in differentiated SH-SY5Y cells using the Glutathione GSH/GSSG Assay Kit (Cat. no.: MAK440; Merck Life Science Kft, Budapest, Hungary). After separation of the cells, the SH-SY5Y cell pellets were lysed in cold buffer containing 50 mM phosphate, pH 7, 1 mM EDTA, and 20 µL of the Scavenger for GSSG measurement. To determine the total glutathione concentration, the cells were homogenized in a cold buffer containing 50 mM phosphate (pH 7) and 1 mM EDTA. After centrifugation, the supernatants were deproteinated using a 5% meta-phosphoric acid solution. Following centrifugation at 14.000× g for 5 min, 6 µL of the supernatant was used to detect glutathione. Optical density was measured at 412 nm wavelength. The total, oxidized, and reduced glutathione concentrations were calculated using the equations provided in the protocol. 2.17. Malondialdehyde Measurements MDA levels were measured using the Malondialdehyde (MDA) Colorimetric Assay Kit (Cat. no.: EEA015; Thermo Fisher Scientific Inc., Waltham, MA, USA). Differentiated SH-SY5Y cells were cultured in 6 cm dishes (Biologix Europe, Hallbergmoos, Germany) at a density of 106 cells/dish. Co-cultures were established and treated as described above. After separation, SH-SY5Y cells were collected and lysed in PBS. After centrifugation, the supernatants were used for MDA detection. Optical density was determined at 532 nm using a Multiskan GO spectrophotometer. The MDA concentration was calculated using a standard curve (0–40 μmol). The results were normalized to the protein content of the supernatant and expressed as μmol/g protein [26]. 2.18. Glutamate Measurement Differentiated SH-SY5Y cells were cultured in 6-well plates (Biologix Europe, Hallbergmoos, Germany) at a density of 5 × 105 cells/well. Co-cultures were established and treated as previously described. Intracellular and extracellular glutamate levels were determined using the Glutamate Assay Kit-WST (Cat. no.: G269; Dojindo EU GmbH, Munich, Germany). After separation, the SH-SY5Y and BV-2 cell pellets were homogenized in Lysis Buffer. After centrifugation, the supernatants were concentrated, and 40 µL of the samples was used for measurements. After adding the working solution, the samples were incubated at 37 °C for 30 min. Extracellular glutamate levels were determined using the supernatant of the co-cultures the same way as in the case of cell lysates. Absorbance was measured at 450 nm. The glutamate levels of the samples were calculated using a glutamate standard curve, and the concentrations were expressed in mM. 2.19. Real-Time PCR Co-cultures were established and treated as previously described. After separation, BV-2 cells were collected from the coverslips using trypsinization and centrifugation. Total RNA was isolated from BV-2 cells using the Aurum Total RNA Isolation Kit (Cat. no.: 7326820; Bio-Rad Inc., Hercules, CA, USA), and complementary DNA (cDNA) was synthesized using the iScript cDNA Kit (Cat. no.: 1708891; Bio-Rad Inc., Hercules, CA, USA) according to the manufacturer’s protocol. Real-time PCR was performed using the Opus 96 Real-Time System (Bio-Rad Inc., Hercules, CA, USA) with iTaq Universal SYBR Green Supermix (Cat. no.: 1725121; Bio-Rad Inc., Hercules, CA, USA). The specificity of each reaction was validated by generating melting curves (Supplementary Figure S1). Relative gene expression was calculated using the Bio-Rad CFX Manager 3.1 software (Bio-Rad Inc., Hercules, CA, USA). For normalization, the β-actin housekeeping gene was used. Relative expression rates were expressed as fold changes relative to those of the control. The gene expression of the controls was regarded as 1 [25]. The primer sequences used in this study are presented in Table 1. 2.20. Enzyme-Linked Immunosorbent Assay (ELISA) The co-cultures were treated as described above. After the treatments, the cell culture medium, SH-SY5Y, and BV-2 cells were collected and stored at −80 °C until analysis. Intracellular cleaved (inactive) poly ADP-ribose polymerase, mono- and oligonucleosomes, cytochrome c, caspase-9, and cleaved caspase-3 concentrations were measured in differentiated SH-SY5Y cells using the Human PARP (Cleaved) [214/215] ELISA Kit (Cat. no.: KHO0741; Thermo Fisher Scientific Inc., Waltham, MA, USA), the Cell Death Detection ELISAPLUS (Cat. no.: CELLDETH-RO; Merck Life Science Kft, Budapest, Hungary), the Human Cytochrome C ELISA Kit (Cat. no.: BMS263; Thermo Fisher Scientific Inc., Waltham, MA, USA), the Human Caspase 9 ELISA Kit (Cat.no.: BMS2025; Thermo Fisher Scientific Inc., Waltham, MA, USA) and the Human Caspase 3 (Cleaved) ELISA Kit (Cat. no.: KHO1091; Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturer’s protocol. Cytokine measurements were performed using the supernatants. Based on the specificity tests provided by the manufacturer, the ELISA kits used are specific for the human or mouse cytokines being tested. The human (SH-SY5Y)- and mouse (BV-2)-originated cytokines were determined using the Human IL-10 ELISA Kit (Cat. no.: BMS215-2), the Mouse IL-10 ELISA Kit (Cat. no.: BMS614), the Human IL-6 ELISA Kit (Cat. no.: KHC0061), the Mouse IL-6 ELISA Kit (Cat. no.: KMC0061), the Human TNFα ELISA Kit (Cat. no.: BMS223-4), and the Mouse TNFα ELISA Kit (Cat. no.: BMS607-3). All cytokine ELISA kits were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Fractalkine concentrations were measured in the cell culture supernatants using the Human Fractalkine ELISA Kit (Cat. no.: EHCX3CL1; Thermo Fisher Scientific Inc., Waltham, MA, USA). Optical density was measured using a Multiskan GO spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) at a wavelength of 450 nm. The concentrations of the target cytokines were calculated using the SkanIt RE 5.0 software. Cyt c and Cleaved PARP levels were expressed as ng/mL, and caspase-9, cleaved caspase-3, and cytokine concentrations were expressed as pg/mL. 2.21. Western Blot For Western blot analysis, differentiated SH-SY5Y cells were cultured in 6 cm dishes (Biologix Europe, Hallbergmoos, Germany) at a density of 106 cells/dish. The co-cultures were established and treated as described above. After cell separation, SH-SY5Y and BV-2 cell pellets were lysed in cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100, pH 7.4). After centrifugation, the protein concentrations were measured using a DC Protein Assay Kit (Cat. no.: 5000112; Bio-Rad Inc., Hercules, CA, USA). Equal amounts of protein samples were separated by SDS-PAGE using a Mini-Protean Tetra Cell system (Bio-Rad Inc., Hercules, CA, USA). The proteins were then transferred to nitrocellulose membranes using a Trans-Blot Turbo Transfer System (Bio-Rad Inc., Hercules, CA, USA). The membranes were blocked with EveryBlot Blocking Buffer (Bio-Rad Inc., Hercules, CA, USA) for 5 min. The following primary antibodies were used in the experiment: anti-NFκB1 p105/p50 IgG (Cat. no.: 12540; 1:1000; overnight at 4 °C, gentle shaking; Cell Signaling Technology Europe, Leiden, The Netherlands) and anti-phospho-p65 IgG (Cat. no.: 3033; 1:1000; overnight at 4 °C, gentle shaking; Cell Signaling Technology Europe, Leiden, The Netherlands). Anti-GAPDH IgG (Cat. no.: G9545; 1:3000; 1 h RT, gentle shaking; Merck Life Science Kft, Budapest, Hungary) was used as the loading control for SH-SY5Y cells, and β-actin (Cat. no.: A5316; 1:2000; 1 h RT, gentle shaking; Merck Life Science Kft, Budapest, Hungary) was used as the loading control for BV-2 cells. Goat anti-rabbit IgG antibody (1:12,000; 1 h, RT, gentle shaking; Merck Life Science Kft., Budapest, Hungary) was used as the secondary antibody. WesternBright ECL chemiluminescent substrate was used to detect the protein bands. The UVITec Alliance Q9 System (UVITec, Cambridge, UK) was used for imaging. NineAlliance Q9 UVITec software (v18.16c ) was used for data analysis. The expression of the target protein was expressed as the percentage of the target to housekeeping protein ratio [25]. 2.22. Data Analysis BBB/permeability data: In the cell impedance and BBB penetration studies, all data are presented as mean ± standard deviation (SD). The number of independent experiments was 4–6 (BBB) and 6–8 (cell impedance). The values were compared using one-way analysis of variance (ANOVA) followed by Bonferroni or Dunnett’s test using GraphPad Prism 5.0 software (GraphPad Software Inc., Boston, MA, USA). Changes were considered statistically significant at p < 0.05. Cellular assays: Three biological replicates were used for each cellular assay. Five technical replicates were used for ROS measurements, and three technical replicates were used for TAC, Cat, GPx, SOD, intracellular iron, GSH/GSSG ratio, MDA, real-time PCR, and ELISA measurements. Western blot images are representative of the three independent experiments. Statistical analyses were performed using the SPSS software (version 24.0; IBM Corporation, Armonk, NY, USA). Statistical significance was determined using one-way ANOVA and Tukey’s post hoc tests. Data are presented as the mean ± SD. The level of significance was set at p < 0.05. Significant differences compared to the controls are indicated by an asterisk (*), and significant alterations compared to the 6-OHDA-treated cells are indicated by a cross symbol (†). 3. Results 3.1. Chemical Synthesis The synthesis of targeted cyclic C5-curcuminoid (8, 9, 11, 12, and 13) and cyclic chalcone (4 and 5) derivatives for this study was performed according to our previous publication [26]. All reagents, reaction conditions, and methods were identical to those previously published. To simultaneously observe the corresponding structures and numbering, we provided the reaction pathways (Figure 4, Figure 5 and Figure 6). 3.2. Effect of Compounds 5, 9, 12, and 13 on the Impedance of Brain Endothelial Cells The four curcuminoid derivatives were tested for the capability to penetrate the BBB. As a first step, the impedance of brain endothelial cell layers was determined (Figure 7), similarly to our previous study [22], which reflects barrier integrity as well as cell response and viability. The impedance profiles remained similar to the control group (shown in red in Figure 7A–D) for most compounds and concentrations, indicating good barrier properties and cell viability. At the 1 h time point (Figure 7E), the 10 µM concentration of compound 9 and the 1 and 10 µM concentrations of compound 12 slightly and transiently increased the cell index values. Since impedance values reflect several cellular parameters simultaneously, including cell adhesion, morphology, membrane properties, and cell–cell contacts, giving a complex biological readout, the small transient impedance elevation can be interpreted either as improved barrier tightness, based on our previous study [34], or membrane-associated changes. However, at later time points, the highest 10 µM concentration of compound 12 decreased cell impedance (Figure 7C) and, after 8 h incubation, caused cell death. Based on these results, permeability experiments were performed at a concentration of 1 µM for all the curcuminoid derivatives. 3.3. Permeability of Compounds 5, 9, 12, and 13 Across the Human Cell-Based BBB Model The human BBB model showed good barrier properties based on the low Papp values for passive paracellular BBB permeability marker molecule SF and transcellular permeability marker EBA (Figure 8), similarly to our previous study characterizing the model [34]. Compound 12 exhibited the highest penetration, 13.6 × 10−6 cm/s, across the BBB model among the four compounds, which was 3-fold higher than the Papp of sodium fluorescein (SF) (Figure 8). Based on our previous results and expertise [42], Papp values above 10–15 × 10−6 cm/s can be considered as good BBB penetration. The penetration of compounds 9 (4.3 × 10−6 cm/s), 5 (4.3 × 10−6 cm/s), and 13 (3 × 10−6 cm/s) was in the range of the Papp of the marker molecule sodium fluorescein (SF; Figure 8). These results indicate the low passive diffusion of curcuminoid derivatives 5, 9, and 13 across the human BBB model. The penetration of the four compounds was determined in cell-free inserts, too. High Papp values were measured for all the derivatives (compound 5: 34.6 × 10−6 cm/s; compound 9: 22.6 × 10−6 cm/s; compound 12: 45.8 × 10−6 cm/s; compound 13: 28.3 × 10−6 cm/s), indicating that the membranes of the inserts were highly permeable to the molecules and indeed the human BBB model was responsible for the low penetration. After the BBB permeability experiments, recovery/mass balance values were also determined (Table 2). The recovery/mass balance value of 70% of compound 13 can be considered good in drug permeability assays [42]. For compounds 5, 9, and 12, low recovery values were measured (Table 2). No cellular uptake was detected for compounds 9 and 13, and less than 3% of compounds 5 and 13 were measured in the cell fraction at the end of the permeability experiment, indicating that the tested derivatives did not enter and were trapped in the brain endothelial cells in significant amounts (Table 2). As a control experiment, the recovery values of the tested derivatives were calculated using only cell-free inserts. Two curcuminoid derivatives showed high recovery values ≥ 70% (compounds 12 and 5), indicating that they did not bind to the membrane of the inserts or the plastic surfaces (Table 2). However, these derivatives showed low recovery values measured in the BBB model; therefore, we speculate that these molecules can be metabolized by brain endothelial cells. The recovery value of compound 13 was within the acceptable range for both the BBB model and cell-free inserts. The recovery values were the lowest for compound 9, measured on both cell-free inserts (63%) and the BBB model (37%), indicating binding to the membrane of the inserts and/or plastic surfaces, as well as metabolism by the cells. 3.4. Cyclic C5-Curcuminoids and Chalcones Reduce the Production of ROS by Increasing Antioxidant Capacity in Co-Cultured SH-SY5Y Cells 6-OHDA treatment significantly increased ROS production and decreased total antioxidant capacity (TAC), suggesting the establishment of oxidative stress (Figure 9A,B). Compounds 5 (p = 0.002), 9 (p = 0.0016), 12 (p = 0.0013), and 13 (p = 0.0002) significantly reduced ROS production compared to 6-OHDA treatment (Figure 9A). Moreover, compound 13 (p = 0.0053) significantly reduced ROS levels compared to those in the control (Figure 9A). In contrast, these compounds significantly increased the total antioxidant capacity of the neurons compared to 6-OHDA treatment, and compounds 9 (p = 0.0039) and 13 (p = 0.0082) showed higher TAC levels than the control (Figure 9B). Compounds 4, 8, and 11 did not reverse the effects of 6-OHDA, suggesting that these compounds do not provide antioxidant protection to SH-SY5Y cells (Figure 9A,B). 3.5. Cyclic C5-Curcuminoids and Chalcones Modify the Activity of the Antioxidant Enzymes in the Co-Cultured SH-SY5Y Cells Considering that TAC evaluates the antioxidant defense provided by both small molecules and enzymes, our objective was to determine the individual contributions of catalase, superoxide dismutase, and glutathione peroxidase antioxidant enzymes to this defense. 6-OHDA did not affect antioxidant enzyme activity, except for GPx, which was reduced in the SH-SY-5Y cells (Figure 10C). Compounds 5 (GPx, p = 0.0041; SOD, p = 0.0018; Cat, p < 0.0084) and 9 (GPx, p = 0.0012; SOD, p = 0.0003; Cat, p < 0.0001) significantly induced the activity of all three enzymes compared to 6-OHDA treatment (Figure 10), suggesting their potent antioxidant effects. Compound 12 significantly increased SOD (p = 0.0013) and GPx (p = 0.0026) activities (Figure 10B,C), whereas compound 13 significantly elevated catalase (p < 0.0001) and GPx (p = 0.0003) activities (Figure 10A,C). Compound 4 significantly increased catalase activities (p = 0.0041), whereas compound 8 reduced them (p = 0.0012) (Figure 10A). Compound 11 was ineffective against antioxidant enzymes. Based on these results, curcuminoid derivatives and chalcones appear to alter the action of antioxidant enzymes differently. Therefore, they contribute to antioxidant defense at different ratios. 3.6. Cyclic C5-Curcuminoids and Chalcones Decrease the Iron-Mediated Oxidative Stress and the Markers of Ferroptosis in the Co-Cultured SH-SY5Y Cells The total iron content of the co-cultured SH-SY5Y cells significantly increased upon 6-OHDA treatment, while in the co-cultured BV-2 cells, reduced iron levels were detected (Figure 11A,B), suggesting iron transport between the two cell types. Compounds 5 (p = 0.001), 9 (p = 0.0048), 12 (p = 0.0023), and 13 (p = 0.0028) lowered iron levels in neurons compared to 6-OHDA treatment (Figure 11A). Interestingly, compound 5 (p = 0.0009) significantly increased the iron levels in the co-cultured BV-2 cells (Figure 11B). The GSH/GSSG ratio indicates the severity of oxidative stress. The GSH/GSSG ratio demonstrated that 6-OHDA treatment increased oxidative stress. Meanwhile, compounds 5 (p = 0.0023), 9 (p = 0.0002), 12 (p < 0.0001), and 13 (p = 0.0002) decreased oxidative stress compared to 6-OHDA treatment in co-cultured SH-SY5Y cells and reached or exceeded control levels (Figure 11C). Compounds 4 (p = 0.001), 8 (p = 0.01), and 11 (p < 0.0001) also reduced oxidative stress but did not reach the control GSH/GSSG ratios (Figure 11C). Malondialdehyde (MDA), a marker of lipid peroxidation, was significantly increased in the 6-OHDA-treated co-cultured SH-SY5Y cells (p < 0.0001) (Figure 11D). All curcuminoids and chalcones, except compound 8 (with the lowest GSH/GSSG ratio), significantly reduced MDA levels compared to 6-OHDA treatment. Compound 5 reduced the MDA levels to the control level, while MDA levels were below the detection limit in the case of cells treated with compounds 9 and 13 (Figure 11D). 3.7. Cyclic C5-Curcuminoids and Cyclic Chalcones Inhibit Apoptosis in the Co-Cultured SH-SY5Y Cells The concentration of cleaved (inactive) PARP significantly increased in the 6-OHDA-treated co-cultured SH-SY5Y cells (p < 0.0001) (Figure 12A). Compounds 5 (p = 0.001), 9 (p < 0.0001), and 12 (p < 0.0001) significantly reduced cleaved PARP levels compared to 6-OHDA treatment. Moreover, compounds 9 and 12 reduced the cleaved PARP concentrations to the control level (Figure 12A), suggesting strong inhibition of DNA fragmentation. The release of histone-associated DNA fragments (mono- and oligonucleosomes) was also monitored to follow DNA damage in differentiated SH-SY5Y cells. 6-OHDA treatment of co-cultured SH-SY5Y cells significantly increased the enrichment factor of oligonucleosomes, suggesting DNA fragmentation by nucleases activated by the intrinsic apoptotic pathway. Compounds 5 (p < 0.0001), 9 (p < 0.0001), 12 (p < 0.0001), and 13 (p < 0.0001) decreased the enrichment factor of histone-associated DNA fragments, suggesting the inhibition of endonucleases and DNA fragmentation (Figure 12B) and apoptosis. 6-OHDA treatment of co-cultured SH-SY5Y cells significantly increased cytochrome c levels compared to the control (p = 0.0062) (Figure 12B). Compounds 5 (p = 0.0007), 9 (p = 0.0106), and 12 (p = 0.0067) significantly reduced cytochrome c concentrations compared to 6-OHDA. Compound 5 significantly reduced cytochrome c levels; compound 13 did not (Figure 12C). Because the total cytochrome c level alone does not prove the activation of apoptosis, the active caspase-9 levels were also measured. 6-OHDA treatment of co-cultured SH-SY5Y cells significantly increased caspase-9 levels (p = 0.0002), whereas compounds 5 (p = 0.0005), 9 (p = 0.0013), 12 (p = 0.0012), and 13 (p = 0.014) significantly reduced them (Figure 12D). In the case of cleaved caspase-3 (effector caspase), increased levels were observed in the 6-OHDA-treated co-cultured SH-SY5Y cells (Figure 12E). Compounds 5 (p = 0.0011), 9 (p = 0.0022), 12 (p = 0.0024), and 13 (p = 0.0031) reduced the levels of cleaved caspase-3 (Figure 12E). Compounds 4 (p = 0.0054) and 8 (p = 0.0074) also reduced cleaved caspase-3, though the effect was less convincing. These results suggest that compounds 5, 9, and 12 possess high anti-apoptotic potential in the 6-OHDA-induced neuronal damage model. Compound 13 also inhibited DNA fragmentation and the levels of active caspase-9 and -3. These results suggest that compound 13 may increase the production of inhibitors of apoptosis (IAPs). 3.8. Cyclic C5-Curcuminoids and Cyclic Chalcones Modify the Intracellular and Extracellular Glutamate Levels in the Co-Cultured Cells Interestingly, similar results were observed in both differentiated SH-SY5Y cells and BV-2 microglia upon 6-OHDA treatment; glutamate levels were significantly elevated (SH-SY5Y p = 0.0075; BV-2 p < 0.0001) (Figure 13A–C). Only compounds 5 (p = 0.02) and 13 (p = 0.0074) reduced intracellular glutamate levels in SH-SY5Y cells (Figure 13A). In contrast, in BV-2 cells, compounds 5 (p = 0.0142), 9 (p = 0.0022), and 12 (p = 0.0079) decreased glutamate levels (Figure 13B). Extracellular glutamate, although it did not reach excitotoxic levels, can exacerbate oxidative stress in differentiated SH-SY5Y cells. Compounds 5 (p = 0.0031), 9 (p = 0.0022), 12 (p = 0.0061), and 13 (p = 0.0006) significantly decreased glutamate release compared to the 6-OHDA treatments (Figure 13C). Iba1 mRNA level upregulation occurs shortly after initiating microglial activation. Interestingly, in addition to 6-OHDA, compounds 4 (p = 0.0003), 11 (p = 0.0001), 13 (p = 0.003) and rasagiline (p = 0.002) increased Iba1 mRNA expression in microglia compared to control (Figure 13D). Compounds 5 (p = 0.0001), 8 (p = 0.0001), 9 (p < 0.0001), and 12 (p < 0.0001) significantly decreased Iba1 mRNA levels compared to 6-OHDA treatment (Figure 13D). Based on these results, compounds 5, 9 (although it did not influence SH-SY5Y glutamate levels), 12, and 13 are promising candidates for reducing microglia-driven oxidative stress and neuronal damage. 3.9. Cyclic C5-Curcuminoids 9, 12, and 13 Increase the Secretion of IL-10 Anti-Inflammatory Cytokine In our study, 6-OHDA treatment did not affect neuronal IL-10 secretion but decreased it in BV-2 cells in co-cultures (Figure 14A). Compounds 5 (p = 0.004), 9 (p = 0.0091), 12 (p = 0.022), and 13 (p = 0.0022), as well as rasagiline (p = 0.0013), significantly increased IL-10 secretion in SH-SY5Y cells compared to 6-OHDA treatment (Figure 14A). In BV-2 microglia, compounds 4 (p = 0.0006), 5 (p = 0.0021), and 8 (p = 0.0007) significantly reduced IL-10 secretion compared to that of the control (Figure 14B). In contrast, compounds 9 (p < 0.0001; p < 0.0001), 11 (p = 0.0005; p < 0.0001), 12 (p < 0.0001; p < 0.0001), and 13 (p = 0.0001; p < 0.0001) significantly elevated IL-10 production in BV-2 cells compared to both 6-OHDA treatment and control (Figure 14B). For compound 5, a different mechanism of action can be hypothesized: in microglia, the reduced IL-10 level tends to maintain a pro-inflammatory state, whereas in neurons, it increases IL-10 production, potentially inhibiting the production of inflammatory cytokines. This may be due to differences in the regulation of cytokine-regulating signaling pathways. 3.10. Cyclic C5-Curcuminoids and Cyclic Chalcones Reduce the Secretion of the Pro-Inflammatory Cytokines IL-6 and TNFα 6-OHDA treatment significantly increased IL-6 and TNFα pro-inflammatory cytokine secretion in both cell types in the co-cultures. It should be noted that SH-SY5Y cells released more IL-6, whereas BV-2 cells secreted more TNFα pro-inflammatory cytokines into the culture medium (Figure 15). All compounds reduced neuronal IL-6 secretion (Figure 15A). In BV-2 cells, only compounds 9 (p = 0.0008) and 13 (p = 0.0349) decreased IL-6 release compared to 6-OHDA treatment (Figure 15B). In the case of TNFα, all compounds except compound 8 decreased TNFα secretion in SH-SY5Y cells (Figure 15C). In BV-2 microglia, compounds 5 (p < 0.0001), 12 (p = 0.0001), and 13 (p = 0.0001) reduced TNFα release compared to 6-OHDA treatment (Figure 15D). Based on the results, we can conclude that only compound 13 is capable of reducing IL-6 and TNFα secretion in both cell types in the co-culture, although compounds 9 and 12 are also promising anti-inflammatory molecules. The mechanism of action of compound 5 appears to vary between the two cell types. In neurons, it decreased the production of both IL-6 and TNFα, whereas in microglia, it only reduced the secretion of TNFα. This discrepancy may result from differences in the regulation of the signaling pathways. 6-OHDA treatment significantly increased fractalkine secretion in co-cultured differentiated SH-SY5Y cells (p = 0.0023) (Figure 15E). Interestingly, compound 8 (p = 0.0038) elevated the fractalkine level after 6-OHDA treatment, suggesting its microglial-activating effect (Figure 15E). Compounds 5 (p < 0.0001), 9 (p = 0.0005), and 12 (p = 0.0003) significantly reduced the release of fractalkine compared to 6-OHDA treatment (Figure 15E). Interestingly, compound 13, which reduced the levels of the pro-inflammatory cytokines IL-6 and TNFα, did not decrease fractalkine secretion. 3.11. Cyclic C5-Curcuminoids and Cyclic Chalcones Alter the Expression of p105, p50, and Phospho-p65, Regulating Inflammation in Co-Cultured SH-SY5Y Cells 6-OHDA treatment significantly increased p105 and p50 protein levels in co-cultured SH-SY5Y cells but only slightly increased P-p65 levels (Figure 16A,B). Compounds 5 (p = 0.0003), 9 (p = 0.0002), 11 (p = 0.0002), 12 (p = 0.0005), and 13 (p = 0.0001) significantly reduced p105 levels compared to 6-OHDA treatment (Figure 16B); however, none of the compounds decreased p50 levels. Moreover, compounds 4 and 8 further increased p50 levels compared to 6-OHDA treatment (Figure 16A,B). The elevation in the p50/p105 protein ratio indicates the activation of the signaling pathway (Figure 16C). In contrast, all compounds, except compounds 4 and 8, significantly reduced P-p65 protein levels compared to 6-OHDA and the controls (Figure 16A,B), suggesting that the anti-inflammatory effects of cyclic C5-curcuminoids and cyclic chalcones are based on the inhibition of p65 phosphorylation in SH-SY5Y cells. In BV-2 cells, 6-OHDA significantly increased the protein levels of p105 (p = 0.0002) but decreased p50 (p < 0.0001) and P-p65 (p = 0.0005) levels (Figure 16D,E). Compounds 4 (p = 0.0002), 5 (p = 0.0002), 9 (p = 0.0022), 11 (p < 0.0011), and 13 (p = 0.0011) significantly reduced p105 levels compared to 6-OHDA treatment alone (Figure 16E). However, compounds 4 (p = 0.0001), 5 (p < 0.0001), 11 (p = 0.0002), and 13 (p < 0.0001) decreased the p50 levels, too (Figure 16D,E). The p50/p105 ratio significantly decreased only after treatment with compounds 5 (p = 0.007) and 13 (p = 0.001) compared to 6-OHDA treatment (Figure 16F). All compounds significantly lowered P-p65 protein levels compared to 6-OHDA and the controls (Figure 16D,E). These results suggest that compounds 5 and 13 exert anti-inflammatory effects in BV-2 cells. However, the other compounds may also possess anti-inflammatory effects by inhibiting p65 phosphorylation. 4. Discussion Neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis are prevalent worldwide [43]. Common features include protein aggregation, oxidative stress, disrupted iron metabolism, ferroptosis, mitochondrial dysfunction, and microglial activation, which drive disease progression [44,45,46]. Microglia protect the brain by monitoring functions, removing materials and damaged cells, supporting neurons, and regulating neuroinflammation through cytokines and chemokines [28,47]. However, chronic activation harms neurons and increases neuronal death. In neurodegenerative diseases, active microglia promote ROS production, oxidative stress, and excess glutamate release, leading to increased cell death [28,48]. Thus, inhibiting microglial activation is a therapeutic issue, while treatments relieve symptoms and slow the disease progression. Natural, bioactive compounds found in plants are under massive investigation to treat neurodegenerative diseases [49,50,51], including BBB protection [13]. Although many natural substances have shown promising results (e.g., curcumin, resveratrol, linalool, geraniol, and limonene), there are some challenges regarding their bioavailability, stability, and ability to cross the blood–brain barrier [52,53,54]. Curcumin is extracted from turmeric (Curcuma longa L., Curcuma domestica L.) [3]. It has been described as an antioxidant and anti-inflammatory molecule [55,56]. It decreased activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and Janus kinase/Signal transducer and activator of transcription (JAK/STAT) signaling pathways and reduced synthesis of pro-inflammatory cytokines such as IL-6, IL-1β, and TNFα [57]. In preclinical studies, inhibition of the NFκB pathway and decreased pro-inflammatory cytokines were central to the BBB-protective effects of curcumin [13]. The major problems associated with curcumin are its hydrophobic nature, low stability, and rapid metabolism [58]. Stability and biological activity have been improved using metal complexes, nanoparticles, and more stable synthetic curcuminoid analogs, including synthetic C5-curcuminoids as neuroprotective agents in mice (including in vitro and in vivo tests and molecular docking validation) and cyclic C5-curcuminoids [15,20]. In our previous study, we examined seven synthetic cyclic C5-curcuminoids and chalcones in monocultures of all-trans retinoic acid-differentiated SH-SY5Y cells. Three cyclic C5-curcuminoids and one chalcone showed potential antioxidant and anti-apoptotic effects, but their anti-inflammatory effects remain incompletely investigated [26]. In the present study, we developed an in vitro neuronal damage co-culture model using differentiated SH-SY5Y cells, BV-2 microglia, and 6-OHDA to mimic oxidative stress in SH-SY5Y cells and monitor the effects of microglia on neurons. Therefore, it was possible to prove the advantageous effects of the synthetic cyclic C5-curcuminoids and chalcones even in the presence of microglia, which, in an active state, can contribute to neuronal loss [28,48]. 6-OHDA treatment enhances ROS production, contributing to oxidative stress [59]. It also triggers iron accumulation by altering transferrin receptor 1 and ferroportin expression [60,61]. Increased labile iron activates the Fenton reaction, whereas 6-OHDA auto-oxidation generates superoxide anions and hydrogen peroxide [62]. Mitochondrial respiratory chain inhibition further increases superoxide production, causing mitochondrial damage and reducing energy production [63]. Antioxidant enzymes eliminate reactive oxygen radicals in compartments [64]. GPx protects membranes from lipid peroxidation and ferroptosis [65], SOD protects against superoxides, and catalase eliminates hydrogen peroxide [66,67]. Regarding antioxidant protection, ROS and TAC levels and GPx and SOD activities correlated with measurements in SH-SY5Y monocultures from our publication [26]. However, BV-2 microglia in co-cultures altered compound effectiveness. In co-cultures, compounds 5, 9, 12, and 13 enhanced protection of neurons via ROS, TAC, GPx, and catalase measurements with values lower than those observed in monocultures [26]. Compounds 5 and 9 increased the activities of all three antioxidant enzymes, suggesting that synthetic C5-curcuminoids affect defense mechanisms. Based on the GSH/GSSG ratio, all tested compounds reduced oxidative stress compared to 6-OHDA in differentiated SH-SY5Y cells, but only compounds 5, 9, 12, and 13 restored control levels, possibly through GSH synthesis and GPx-GR activity [68]. Elevated intracellular iron content, especially in the labile iron pool containing reactive ferrous iron, can strongly contribute to iron-mediated oxidative stress, affecting glutathione levels and GPx activity [69]. In neurodegeneration, microglia may also contribute to neuronal iron accumulation by releasing iron and triggering its uptake into the neurons, which may enhance lipid peroxidation, leading to ferroptosis [70,71,72]. In co-cultures, 6-OHDA-treated SH-SY5Y cells exhibited increased iron levels, supporting 6-OHDA-induced iron accumulation. Compounds 5, 9, 12, and 13 maintained control iron levels in neurons after 6-OHDA exposure, protecting against iron-mediated ROS production. In BV-2 cells, compounds 9, 12, and 13 did not alter iron levels, whereas compound 5 increased microglial iron. These results indicate that BV-2 cells likely alter the expression of genes involved in iron uptake and release [40]. Malondialdehyde level, which is a potential marker for oxidative stress and an indicator of lipid peroxidation [73], significantly decreased in the differentiated SH-SY5Y cells using three cyclic C5-curcuminoids (9, 12, and 13) and one chalcone (5), suggesting balanced oxidative protection and reduced oxidants. Apoptosis contributes to neuronal loss in neurodegenerative diseases [74]. DNA damage in Parkinson’s disease activates PARP-1, responsible for DNA repair. During apoptosis, PARP-1 is cleaved into 89 and 24 kDa fragments, leading to the inactivation of the repair enzyme. Consequently, DNA fragmentation and cell death occur [75]. In our experiments, 6-OHDA treatment significantly increased the concentration of cleaved PARP in differentiated SH-SY5Y cells in co-cultures, whereas compounds 5, 9, and 12 reversed the effect of 6-OHDA, suggesting a decrease in DNA damage. Interestingly, compound 13, which has a strong antioxidant defense-activating effect, did not reverse the effect of 6-OHDA on PARP cleavage. The inhibition of DNA fragmentation was proven by the significantly decreased level of mono- and oligonuceosomes in the cytosol of the SH-SY5Y cells upon treatment with compounds 5, 9, 12, and 13. Oxidative stress-mediated mitochondrial dysfunction initiates the release of cytochrome c from the mitochondria, activating the caspase cascade. At the end of programmed cell death, the final caspase, executioner caspase-3, is activated [76,77]. Total cytochrome c levels decreased in the co-cultured SH-SY5Y cells treated with compounds 5, 9, 12, and 13. However, this phenomenon did not prove the activation of the mitochondrial apoptotic pathway. Caspase-9, activated by the apoptosome, and cleaved caspase-3 levels support the apoptosis-inhibitory effects of compounds 5, 9, 12, and 13. This may be due to decreased oxidative damage to the mitochondria. Interestingly, in the case of caspase-3 activation, not only the aforementioned four compounds but also compounds 4 and 8 successfully decreased the level of active caspase-3. One possible explanation for this is that these compounds may increase the expression of inhibitors of apoptosis (IAPs) [78]. Microglia expressing ionized calcium-binding adapter molecule (Iba1) activation marker secrete pro-inflammatory cytokines (TNFα, IL-6, IL-1), driving neuroinflammation [79,80]. Furthermore, oxidative stress in the brain or the release of pro-inflammatory cytokines from neurons rapidly upregulates Iba1 expression, and microglia turn to an active state [81], exacerbating oxidative stress and inflammation, and contributing to neuronal damage [33]. The expression of Iba1 mRNA increases shortly after the onset of activation; however, this alteration alone does not confirm microglial activation. It has been revealed that 6-OHDA treatment upregulated Iba1 expression in co-cultured BV-2 cells, whereas compounds 5, 8, 9, and 12 significantly decreased the expression of this marker. Together with the elevated secretion of pro-inflammatory cytokines, specifically TNFα and IL-6, by microglia in a co-culture with 6-OHDA-pretreated differentiated SH-SY5Y cells, this indicates the development of an inflammatory phenotype. The production of inflammatory cytokines requires enhanced activity of the signaling pathways associated with their activation. Activated microglia release glutamate, an excitotoxin, exacerbating neuronal loss by activating receptors and causing Ca homeostasis disruption, ROS production, mitochondrial dysfunction, and inflammation [82,83]. In neurodegeneration, neuronal glutamate activates microglial glutamatergic receptors, aggravating neuroinflammation and further impairing antioxidant defense [83,84,85]. Interestingly, glutamate production in BV-2 cells decreased only with compounds 5, 9, and 12. In differentiated co-cultured SH-SY5Y cells, only compounds 5 and 13 effectively decreased glutamate production compared to 6-OHDA treatment. Intracellular glutamate levels do not underlie the glutamate-mediated excitotoxicity. The glutamate release was also measured in the culture medium of the co-cultures, showing decreasing levels in the case of compounds 5, 9, 12, and 13. However, in this case, it is not possible to separate human- and mouse-originating glutamate concentrations. In this model, we cannot achieve excitotoxic levels of glutamate, since BV-2 microglia can release around 200–300 µM glutamate. However, the elevated intracellular glutamate levels in BV-2 microglia and the 200–300 µM extracellular glutamate in the co-culture model can drive oxidative stress in SH-SY5Y cells [86,87]. Therefore, we cannot speak about classical receptor-mediated excitotoxicity, but it is hypothesized that glutamate modifies the activity of the cystine/glutamate antiporter (SLC17A). Consequently, it decreases GSH levels (decreased GSH/GSSG ratio), as well as the activity of glutathione peroxidase, which were both observed in the 6-OHDA pre-treated SH-SY5Y cells of the co-cultures. Microglial activation is closely associated with neuroinflammation. In the brain, IL-10, an anti-inflammatory cytokine released by neurons, astrocytes, and microglia, contributes to maintaining the normal function and survival of the brain cells [88]. Downregulation of IL-10 promotes the activation of microglia towards the pro-inflammatory state [89]. Synthetic cyclic C5-curcuminoids (9, 12, and 13) and chalcone (5) significantly induced IL-10 secretion from co-cultured differentiated SH-SY5Y cells. However, compound 5 did not have the same effect on BV-2 microglia, suggesting a different mechanism of action for this chalcone in the regulation of cytokine synthesis. Compounds 9, 11, 12, and 13 increased microglial IL-10 production, suggesting their anti-inflammatory roles in the 6-OHDA-induced neuronal damage model. For the pro-inflammatory cytokines TNFα and IL-6, all compounds decreased their levels (except for compound 4 for IL-6 and compound 8 for TNFα) in the neurons. In microglia, compounds 9 and 13 downregulated IL-6, whereas compounds 5, 12, and 13 reduced TNFα. Compound 13 decreased both pro-inflammatory cytokines in both cell types in the co-culture. The distinct effects of compound 5 on IL-6 and TNFα indicate that it may exert differential actions on neurons and microglia. This variation could be attributed to the distinct regulation of inflammatory pathways. In neurons treated with compound 5, the JAK1/STAT3 pathway can be activated by IL-10, resulting in anti-inflammatory effects. Conversely, in microglia, the activation of JAK1/STAT3 is induced by IL-6, which subsequently promotes additional IL-6 synthesis [90,91]. Microglial activation and pro-inflammatory cytokine expression are regulated by fractalkine/fractalkine receptor (CX3CR1) interaction [92]. Soluble fractalkine, released from neuronal membrane-bound fractalkine, binds microglial receptors and upregulates the NFκB inflammatory pathway in a concentration-dependent manner and the mitogen-activated protein kinase (MAPK) pathway, regulating cell cycle, division, and apoptosis [93,94]. Soluble fractalkine contributes to neurodegenerative disease progression [95] and enhances neuronal iron accumulation, oxidative stress, and ferroptosis [96]. Its downregulation in co-cultured differentiated SH-SY5Y cells treated with compounds 5, 9, and 12 correlated with reduced pro-inflammatory cytokine expression, whereas compound 13 caused only a slight decrease in fractalkine secretion. In the case of compound 13, although IL-6 and TNFα secretion decreased, this was inconsistent with the increased expression of Iba1 and the levels of fractalkine. Disruption of fractalkine signaling, such as the internalization of CX3CR1 on microglia due to increased soluble fractalkine levels or the loss of membrane-bound fractalkine on SH-SY5Y cells, can lead to microglial activation [92]. In the case of compound 13, the fractalkine level remained unchanged in comparison to 6-OHDA treatment, which may contribute to the increased expression of Iba1 mRNA. On the other hand, the discrepancy between fractalkine, Iba1, and pro-inflammatory cytokines may be due to the regulation of alternative signaling pathways: besides the major inflammatory pathway NFκB, other signaling pathways, such as C/EBPβ, MAPK/p38, JAK/STAT, and Akt [97,98], may also increase the expression of certain cytokines such as IL-6, IL-1β, IL-8, and TNFα [99]. Western blot analysis of NFκB transcription factors also supports this hypothesis. In the co-cultured differentiated SH-SY5Y cells, 6-OHDA treatment increased p105, p50, and P-p65 expression, which correlated with pro-inflammatory cytokine and fractalkine secretion. Compounds 5, 9, 11, 12, and 13 significantly reversed the effect of 6-OHDA by decreasing the expression of P-p65, which was observed in the alterations in pro-inflammatory cytokine production. In microglia, compounds 4, 5, 9, 11, and 13 significantly reduced the p105 protein levels and P-p65, whereas compounds 4, 5, 11, and 13 decreased p50 levels. However, only compounds 5 and 13 significantly decreased the p50/p105 ratio, suggesting the downregulation of the signaling pathway. Based on these observations, synthetic cyclic C5-curcuminoids appear to mainly act by inhibiting p65 phosphorylation in SH-SY5Y cells, but in BV-2 cells they may also act via the downregulation of p50. Concerning structure–activity relationship (SAR) analysis, we share the following points. This study selected compounds 4, 5, 8, 9, 11, 12, and 13 for testing as pairs with slight structural differences: phenolics (5, 9, 12, and 13) and non-phenolics (4, 8, and 11), in which the phenolic function was blocked by a hardly removable methyl substituent. This distinction indicates a biochemical difference: in biological hydrogen transfer reactions, phenolics are hydrogen donor groups, whereas non-phenolic compounds 4, 8, and 11 are neutral in this respect. Such enzyme-catalyzed hydrogen (hydride) transfer reactions are well known and ubiquitous in biological media [100,101]. The two groups could also be separated by biological efficacy, except for a few cases, throughout testing in this study, according to Section 3.3, Section 3.4, Section 3.5, Section 3.6, Section 3.7, Section 3.8, Section 3.9, Section 3.10 and Section 3.11 above. The hydrogen-donor phenolic group was, in most results, closer to protectivity than the non-phenolic group. Compounds 4, 8, and 11 were cytotoxic, owing to methyl substitution. This biological difference is due to the dual reactivity of the benzylidene double bond in the structure: the phenolic function allows rearrangements of 5, 9, 12, and 13 for dehydrogenation (hydrogen donation) while the methyl blockade results in thiol addition over the benzylidene double bond (thio-Michael reaction), leading to cytotoxicity [26]. Phenolic OH allows molecules to become antioxidant, whereas the methyl substituent blocks this. This was visible against ROS: non-phenolic 4, 8, and 11 did not reduce ROS. Compound 13 with a monocarboxylic function on the central piperidone ring, compound 9 with an alkyl OH, and compound 12 with an NH function at the same position were active antioxidants. For the proposed transition products of the neuroprotection-promoter hydrogen-donor cyclic C5-curcuminoids, see [26]. Derivatives 9 and 13 showed an increase in catalase and GPx induction, whereas the non-phenolic compounds remained neutral. This cannot be explained by the hydrogen donor ability. The OH group in the central cyclohexanone ring of 9 and the NH moiety in the piperidone ring of 12 inhibited DNA fragmentation, suggesting a high anti-apoptotic potential in this model. Reduction in microglial activation and glutamate production was observed with compounds 9 and 12. Phenolic cyclic chalcone 5 exhibited anti-apoptotic potential. The differences in the BBB penetrations of 5, 9, 12, and 13 cannot be explained merely by structural polarity. These curcuminoids are polar due to the presence of phenolic OH, secondary NH, and free carboxylic acid moieties. Binding to BSA and transporter macromolecules in human cells may affect BBB penetration. Further investigations are required to answer these questions. 5. Limitations However, the results are promising and suggest the possibility of developing new therapies for neurodegenerative diseases. The three cyclic C5-curcuminoids (compounds 9, 12, and 13) and one cyclic chalcone (compound 5) require further investigation. The synthetic cyclic C5-curcuminoids were tested at individually selected concentrations, highlighting that the observed differences in biological effects are not due to intrinsic compound potency. Instead, these differences may reflect the varying doses used. It is crucial to interpret the results as the effects of each compound at its specific concentration, rather than as a ranking of potency or efficacy. To accurately compare the relative potency of these compounds, future research should employ matched equimolar or equitoxic concentrations and include a compound-vs-compound statistical analysis, which was not part of the current study design. Our studies were limited to in vitro co-culture, utilizing human SH-SY5Y cells and mouse-derived BV-2 microglia. This setup ensured that cytokines secreted by the cells could be specifically quantified, thereby allowing the effects of synthetic cyclic C5-curcuminoids on neurons and microglia to be distinguished. It should be noted that the pro-inflammatory cytokine IL-1β was not quantified, precluding the assessment of its impact. Additionally, our experiments were conducted at 24 h intervals, highlighting the necessity for supplementary long-term studies. It is important to further enhance the stability of these compounds through appropriate modifications and formulations, enabling in vivo studies. Investigating and characterizing the oral bioavailability, absorption, and metabolism of curcuminoid derivatives is imperative, as is monitoring the utilization of compounds entering the circulation, their penetration of the blood–brain barrier, and the consequent alterations in biological effects in in vivo models. Furthermore, employing combinations of the compounds under investigation may optimize antioxidant, anti-apoptotic, and anti-inflammatory effects. 6. Conclusions Based on these results, it can be concluded that compounds 5, 9, 12, and 13, each evaluated at its own individually selected sub-IC50 concentration, are promising candidates for the treatment of neuronal damage in the presence of microglia, which are major contributors to disease progression. At the tested concentration, compound 13 increased catalase and GPx activity and reduced markers of iron-mediated oxidative stress and ferroptosis. Compound 9 also reduced ferroptosis markers and inhibited microglial activation and glutamate synthesis. Compound 5 exhibited consistent anti-apoptotic effects on PARP, cytochrome c, and caspase-9 and 3 markers. Compound 13 reduced the secretion of pro-inflammatory cytokines (IL-6 and TNFα) in both cell types. Because the compounds were tested at different absolute and IC50-relative concentrations, these results describe the effects of each compound under its own tested condition and should not be interpreted as a potency ranking across all compounds. Depending on the prioritized biological property, all four compounds are candidates for further neuroprotective development, ideally at matched concentrations in follow-up studies. The BBB experiments demonstrated the potential for brain penetration in the case of one cyclic C5-curcuminoid, compound 12. The permeability of compounds 5, 9, and 13 can be improved through further modifications and formulations, which could facilitate BBB crossing. From a translational perspective, compound 12 is the primary candidate for in vivo follow-up, where brain and plasma exposure and the persistence of the antioxidant and anti-inflammatory effects observed here could be evaluated in a rodent model of the oxidative dopaminergic injury reproduced in vitro by 6-OHDA. In contrast, compounds 5, 9, and 13 have limited permeability points, indicating that formulation-based approaches are more suitable than in vivo approaches as the immediate direction. For compound 12, which showed adequate permeability, the poor aqueous solubility and extensive presystemic metabolism characteristics of curcuminoids would be the primary obstacles to in vivo evaluation, which could be addressed by solid-state and particle-engineering approaches, such as amorphous solid dispersions, nanocrystalline suspensions, cocrystals, or lipid-based delivery systems. In contrast, for compounds 5, 9 and 13, the limitation is passive diffusion rather than dissolution and is therefore unlikely to be overcome by solubility enhancement alone.